Literature DB >> 19997967

Elevated interleukin-21 correlated to Th17 and Th1 cells in patients with immune thrombocytopenia.

Xiaojuan Zhu1, Daoxin Ma, Jingbo Zhang, Jun Peng, Xun Qu, Chunyan Ji, Ming Hou.   

Abstract

BACKGROUND: Interleukin-21 (IL-21) is critical in the development of autoimmune diseases. The role of IL-21 in the pathogenesis of immune thrombocytopenia (ITP) remains unknown.
MATERIALS AND METHODS: We examined the expression of IL-21, IL-17, and interferon (IFN)-gamma in ITP patients and controls by enzyme-linked immunosorbent assay and flow cytometry. Detection of specific anti-platelet GPIIb/IIIa and/or GPIb/IX autoantibodies was measured by modified monoclonal antibody specific immobilization of platelet antigens.
RESULTS: IL-21 was expressed on both CD3(+)CD8(-) T cells and CD3(+)CD8(+) T cells by flow cytometry. Plasma IL-21 level and the percentage of CD3(+)CD8(-)IL-21(+) T cells and CD3(+)CD8(+)IL-21(+) T cells were significantly elevated in ITP patients compared to controls. The percentage of CD3(+)CD8(-)IL-17(+) T (Th17), CD3(+)CD8(-)IFN-gamma(+) T (Th1), and CD3(+)CD8(+)IFN-gamma(+) T (Tc1) cells also significantly increased in ITP patients. Moreover, we found a significant positive correlation between CD3(+)CD8(-)IL-21(+) T cells and Th17 cells. In addition, a positive correlation between CD3(+)CD8(-)IL-21(+) T cells and Th1 cells was also found.
CONCLUSION: Together, our results indicated a possible role of IL-21 in ITP patients correlated to Th17 and Th1 cells, and blockade of IL-21 may be a reasonable therapeutic strategy for ITP especially those with active disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19997967     DOI: 10.1007/s10875-009-9353-1

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  30 in total

1.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

Authors:  Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

2.  Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies.

Authors:  Chunhong Zhao; Xiaofang Li; Feng Zhang; Lin Wang; Jun Peng; Ming Hou
Journal:  Haematologica       Date:  2008-09       Impact factor: 9.941

3.  Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis.

Authors:  Jonathan M Coquet; Sumone Chakravarti; Mark J Smyth; Dale I Godfrey
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

4.  IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression.

Authors:  Deborah Herber; Thomas P Brown; Spencer Liang; Deborah A Young; Mary Collins; Kyri Dunussi-Joannopoulos
Journal:  J Immunol       Date:  2007-03-15       Impact factor: 5.422

5.  Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis.

Authors:  Jörg H W Distler; Astrid Jüngel; Otylia Kowal-Bielecka; Beat A Michel; Renate E Gay; Haiko Sprott; Marco Matucci-Cerinic; Meike Chilla; Kristian Reich; Joachim R Kalden; Ulf Müller-Ladner; Hanns M Lorenz; Steffen Gay; Oliver Distler
Journal:  Arthritis Rheum       Date:  2005-03

6.  IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response.

Authors:  Mari Strengell; Timo Sareneva; Don Foster; Ilkka Julkunen; Sampsa Matikainen
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

7.  T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura.

Authors:  Bob Olsson; Per-Ola Andersson; Margareta Jernås; Stefan Jacobsson; Björn Carlsson; Lena M S Carlsson; Hans Wadenvik
Journal:  Nat Med       Date:  2003-08-24       Impact factor: 53.440

Review 8.  The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer.

Authors:  Rosanne Spolski; Warren J Leonard
Journal:  Curr Opin Immunol       Date:  2008-06-12       Impact factor: 7.486

Review 9.  Interleukin-21 signaling: functions in cancer and autoimmunity.

Authors:  Ian D Davis; Kresten Skak; Mark J Smyth; Paul E G Kristjansen; Dennis M Miller; Pallavur V Sivakumar
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531

10.  Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells.

Authors:  Andrea L Wurster; Vikki L Rodgers; Abhay R Satoskar; Matthew J Whitters; Deborah A Young; Mary Collins; Michael J Grusby
Journal:  J Exp Med       Date:  2002-10-07       Impact factor: 14.307

View more
  27 in total

Review 1.  Piecing together the humoral and cellular mechanisms of immune thrombocytopenia.

Authors:  Lisa J Toltl; Ishac Nazi; Reza Jafari; Donald M Arnold
Journal:  Semin Thromb Hemost       Date:  2011-11-18       Impact factor: 4.180

2.  Effects of high-dose dexamethasone on regulating interleukin-22 production and correcting Th1 and Th22 polarization in immune thrombocytopenia.

Authors:  Jiang Cao; Chong Chen; Li Li; Zeng Ling-yu; Li Zhen-yu; Yan Zhi-ling; Chen Wei; Cheng Hai; Wei Sang; Xu Kai-lin
Journal:  J Clin Immunol       Date:  2012-06       Impact factor: 8.317

3.  Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia.

Authors:  Daria Sollazzo; Sara Trabanelli; Antonio Curti; Nicola Vianelli; Roberto Massimo Lemoli; Lucia Catani
Journal:  Haematologica       Date:  2011-02-28       Impact factor: 9.941

4.  Insufficient secretion of IL-10 by Tregs compromised its control on over-activated CD4+ T effector cells in newly diagnosed adult immune thrombocytopenia patients.

Authors:  Feng Li; Lili Ji; Weiguang Wang; Fanli Hua; Yanxia Zhan; Shanhua Zou; Ling Yuan; Yang Ke; Zhihui Min; Dongli Song; Lihua Sun; Hao Chen; Yunfeng Cheng
Journal:  Immunol Res       Date:  2015-03       Impact factor: 2.829

5.  Interleukin-21-producing HIV-1-specific CD8 T cells are preferentially seen in elite controllers.

Authors:  LaTonya D Williams; Anju Bansal; Steffanie Sabbaj; Sonya L Heath; Wei Song; Jianming Tang; Allan J Zajac; Paul A Goepfert
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

6.  The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia.

Authors:  Andreia Maria Camargos Rocha; Cláudia Souza; Gifone Aguiar Rocha; Fabrício Freire de Melo; Nelma Cristina Diogo Clementino; Marília Campos Abreu Marino; Adriana Bozzi; Maria Luiza Silva; Olindo Assis Martins Filho; Dulciene Maria Magalhães Queiroz
Journal:  Haematologica       Date:  2011-10       Impact factor: 9.941

7.  Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia.

Authors:  Shuang Yu; Chuanfang Liu; Lanhua Li; Tian Tian; Min Wang; Yu Hu; Cunzhong Yuan; Lei Zhang; Chunyan Ji; Daoxin Ma
Journal:  Lab Invest       Date:  2014-12-08       Impact factor: 5.662

8.  Suppressed Th17 levels correlate with elevated PIAS3, SHP2, and SOCS3 expression in CD4 T cells during acute simian immunodeficiency virus infection.

Authors:  Sandra L Bixler; Netanya G Sandler; Daniel C Douek; Joseph J Mattapallil
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

9.  Immune activation is associated with CD8 T cell interleukin-21 production in HIV-1-infected individuals.

Authors:  LaTonya D Williams; Nilesh Amatya; Anju Bansal; Steffanie Sabbaj; Sonya L Heath; Irini Sereti; Paul A Goepfert
Journal:  J Virol       Date:  2014-06-18       Impact factor: 5.103

Review 10.  Immune dysregulation in immune thrombocytopenia.

Authors:  Karina Yazdanbakhsh; Hui Zhong; Weili Bao
Journal:  Semin Hematol       Date:  2013-01       Impact factor: 3.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.